[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $gmab Genmab is acquiring Merus for $X billion, leading to a surge in community engagement and positive sentiment around the project. ### About $gmab A cryptocurrency project. ### Insights [#](/topic/$gmab/insights) - $gmab posts created is up XXXXX% from the previous week. ### Engagements: XXXXX [#](/topic/$gmab/interactions) ---  [Engagements 24-Hour Time-Series Raw Data](/topic/$gmab/time-series/interactions.tsv) **Current Value**: XXXXX **Daily Average**: XXXXX **1 Week**: XXXXXX -XX% **1 Month**: XXXXXXX +223% **1-Year High**: XXXXXXX on 2025-10-06 **1-Year Low**: XXX on 2025-08-02 | Social Network | X | | -------------- | - | | Engagements | XXXXX | ### Mentions: XX [#](/topic/$gmab/posts_active) ---  [Mentions 24-Hour Time-Series Raw Data](/topic/$gmab/time-series/posts_active.tsv) **Current Value**: XX **Daily Average**: XX **1 Month**: XXX +54% **1-Year High**: XXX on 2025-06-27 **1-Year Low**: XX on 2025-04-27 | Social Network | X | | -------------- | - | | Mentions | XXX | ### Creators: XX [#](/topic/$gmab/contributors_active) ---  [Creators 24-Hour Time-Series Raw Data](/topic/$gmab/time-series/contributors_active.tsv) XX unique social accounts have posts mentioning $gmab in the last XX hours which is down XXXX% from XX in the previous XX hours **Daily Average**: XX **1 Month**: XXX +105% **1-Year High**: XXX on 2025-06-27 **1-Year Low**: XX on 2025-04-27 The most influential creators that mention $gmab in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@JacobPlieth](/creator/twitter/JacobPlieth) | X | XXXXXX | X | XXX | | [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) | X | XXXXX | X | XXX | | [@HottestStockNow](/creator/twitter/HottestStockNow) | X | XXXXX | X | XXX | | [@MichelleF_Davis](/creator/twitter/MichelleF_Davis) | X | XXXXX | X | XX | | [@PhilipHemme](/creator/twitter/PhilipHemme) | X | XXXXX | X | XX | | [@EgidiusLambrech](/creator/twitter/EgidiusLambrech) | X | XXX | X | XX | | [@investseekers](/creator/twitter/investseekers) | X | XXXXX | X | XX | | [@stocksguide_](/creator/twitter/stocksguide_) | X | XXXXX | X | XX | | [@SamFazeli8](/creator/twitter/SamFazeli8) | X | XXXXX | X | XX | | [@PersimmonTI](/creator/twitter/PersimmonTI) | XX | XXXXXX | X | XX | [View More](/list/creators/$gmab/100) ### Sentiment: XX% [#](/topic/$gmab/sentiment) ---  [Sentiment 24-Hour Time-Series Raw Data](/topic/$gmab/time-series/sentiment.tsv) **Current Value**: XX% **Daily Average**: XX% **1 Week**: XXX% no change **1 Month**: XX% +7% **1-Year High**: XXX% on 2025-05-10 **1-Year Low**: XX% on 2025-09-14 **Most Supportive Themes** - **Community Engagement:** (45%) Positive sentiment around project updates and community involvement. - **Technological Advancements:** (30%) Excitement regarding new features and technological progress. **Most Critical Themes** - **Market Volatility:** (15%) Concerns about price fluctuations and market uncertainty. - **Competition:** (10%) Discussion of competing projects and their potential impact. Network engagement breakdown: | Network | Positive | % | Neutral | % | Negative | % | | ------- | -------- | - | ------- | - | -------- | - | | X | XXXXX | XX% | XXXXX | XX% | XX | X% | | | | | | | | | | Total | XXXXX | XX% | XXXXX | XX% | XX | X% | **Top assets mentioned** In the posts about $gmab in the last XX hours [Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Johnson & Johnson (JNJ)](/topic/johnson-johnson) [Johnson & Johnson (JNJ)](/topic/$jnj) [Novo-Nordisk (NVO)](/topic/$nvo) [AstraZeneca PLC (AZN)](/topic/$azn) [AbbVie Inc (ABBV)](/topic/$abbv) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [HCA Healthcare Inc (HCA)](/topic/$hca) [Pfizer, Inc. (PFE)](/topic/$pfe) [Bitcoin Incognito (XBI)](/topic/$xbi) **Top topics mentioned** In the posts about $gmab in the last XX hours [$gmabco](/topic/$gmabco), [stocks healthcare](/topic/stocks-healthcare), [$mrus](/topic/$mrus), [stocks](/topic/stocks), [acquisition](/topic/acquisition), [$8b](/topic/$8b), [stocks technology](/topic/stocks-technology), [johnson johnson](/topic/johnson-johnson), [stocks financial services](/topic/stocks-financial-services), [$jnj](/topic/$jnj), [$nvo](/topic/$nvo), [$azn](/topic/$azn), [investment](/topic/investment), [$abbv](/topic/$abbv), [eli lilly](/topic/eli-lilly), [$novcde](/topic/$novcde), [$hca](/topic/$hca), [$pfe](/topic/$pfe), [denmark](/topic/denmark), [$xbi](/topic/$xbi), [$bmrn](/topic/$bmrn), [$lly](/topic/$lly), [danish krone](/topic/danish-krone), [$ggndf](/topic/$ggndf), [breakthrough](/topic/breakthrough), [$argx](/topic/$argx), [$psnl](/topic/$psnl), [stocks banks](/topic/stocks-banks), [targets](/topic/targets), [combo](/topic/combo), [stocks communication services](/topic/stocks-communication-services), [$mrk](/topic/$mrk), [$bntx](/topic/$bntx), [taiwan semiconductor](/topic/taiwan-semiconductor), [$bbio](/topic/$bbio), [$pypl](/topic/$pypl), [longterm](/topic/longterm), [quarterly earnings](/topic/quarterly-earnings), [stocks consumer cyclical](/topic/stocks-consumer-cyclical), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [$tdoc](/topic/$tdoc), [$uhs](/topic/$uhs), [$cyh](/topic/$cyh), [$novob](/topic/$novob), [$dsv](/topic/$dsv), [$elan](/topic/$elan), [investments](/topic/investments), [stocks industrials](/topic/stocks-industrials), [$97share](/topic/$97share), [$googl](/topic/$googl), [$asnd](/topic/$asnd), [$sobi](/topic/$sobi), [$367b](/topic/$367b), [davis](/topic/davis), [medtronic](/topic/medtronic), [$hrmy](/topic/$hrmy), [jacob](/topic/jacob), [costa rican colon](/topic/costa-rican-colon), [coins made in usa](/topic/coins-made-in-usa), [microsoft](/topic/microsoft), [$spgi](/topic/$spgi), [$danskeco](/topic/$danskeco), [royalty](/topic/royalty), [ares capital corp](/topic/ares-capital-corp), [procter gamble](/topic/procter-gamble), [stocks consumer defensive](/topic/stocks-consumer-defensive), [$209b](/topic/$209b), [$8bn](/topic/$8bn), [$55bn](/topic/$55bn), [debt](/topic/debt), [$dwtx](/topic/$dwtx), [people with](/topic/people-with), [$novo](/topic/$novo), [dough](/topic/dough), [$36b](/topic/$36b), [$105m](/topic/$105m), [$124m](/topic/$124m), [$meli](/topic/$meli), [salesforce](/topic/salesforce), [$dsnky](/topic/$dsnky), [$43b](/topic/$43b), [$emx](/topic/$emx), [$enlt](/topic/$enlt), [all the](/topic/all-the), [$1325sh](/topic/$1325sh), [approved](/topic/approved), [$zlab](/topic/$zlab), [$pfes](/topic/$pfes), [china](/topic/china), [make a](/topic/make-a), [stocks utilities](/topic/stocks-utilities), [coins defi](/topic/coins-defi), [coins dao](/topic/coins-dao), [$dy](/topic/$dy), [$caty](/topic/$caty), [fifth third bancorp](/topic/fifth-third-bancorp), [akro akero therapeutics inc](/topic/akro-akero-therapeutics-inc), [novo](/topic/novo), [$52b](/topic/$52b), [$54share](/topic/$54share) ### Top Social Posts [#](/topic/$gmab/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Something tells me $GMAB is about to get eclipsed in folate receptor alpha ADC $LLY $AZN #ESMO25" [X Link](https://x.com/JacobPlieth/status/1979890827871896039) [@JacobPlieth](/creator/x/JacobPlieth) 2025-10-19T12:42Z 30.9K followers, 3058 engagements "Fascinating dynamics in ovarian cancer with multiple ADC programs demonstrating a XX% ORR. FRa in the lead ( $GMAB and $LLY in P3s AZ reported today) CDH6 in P2 (Daiichi reporting P2 data later today) and NaPi2b (Tubulis presented strong results today) in P1. All programs are topo1-based so whoever reaches the market first could render most other programs (15 in the clinic) irrelevant assuming efficacy stays similar #ESMO25" [X Link](https://x.com/ohadhammer/status/1979872159745892489) [@ohadhammer](/creator/x/ohadhammer) 2025-10-19T11:28Z 7840 followers, 6482 engagements "$GMAB Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Updated data from the Phase 1/2 RAINFOL-01 trial showed rinatabart sesutecan (Rina-S) XXX mg/m2 demonstrated 50%confirmed objective response rate (ORR) including two complete responses (CR) regardless of FR expression - A Phase X trial in endometrial cancer is underway U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer" [X Link](https://x.com/MarcJacksonLA/status/1979640271005724830) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-18T20:06Z 7582 followers, XXX engagements "Genmab: Investigational Rinatabart Sesutecan (Rina-S) Achieves Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer $GMAB #Genmab" [X Link](https://x.com/HottestStockNow/status/1979573337409122684) [@HottestStockNow](/creator/x/HottestStockNow) 2025-10-18T15:40Z 2717 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$gmab
Genmab is acquiring Merus for $X billion, leading to a surge in community engagement and positive sentiment around the project.
About $gmab
A cryptocurrency project.
Insights #
- $gmab posts created is up XXXXX% from the previous week.
Engagements: XXXXX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
1 Week: XXXXXX -XX%
1 Month: XXXXXXX +223%
1-Year High: XXXXXXX on 2025-10-06
1-Year Low: XXX on 2025-08-02
| Social Network | X |
|---|---|
| Engagements | XXXXX |
Mentions: XX #
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1 Month: XXX +54%
1-Year High: XXX on 2025-06-27
1-Year Low: XX on 2025-04-27
| Social Network | X |
|---|---|
| Mentions | XXX |
Creators: XX #
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning $gmab in the last XX hours which is down XXXX% from XX in the previous XX hours
Daily Average: XX
1 Month: XXX +105%
1-Year High: XXX on 2025-06-27
1-Year Low: XX on 2025-04-27
The most influential creators that mention $gmab in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @JacobPlieth | X | XXXXXX | X | XXX |
| @MarcJacksonLA | X | XXXXX | X | XXX |
| @HottestStockNow | X | XXXXX | X | XXX |
| @MichelleF_Davis | X | XXXXX | X | XX |
| @PhilipHemme | X | XXXXX | X | XX |
| @EgidiusLambrech | X | XXX | X | XX |
| @investseekers | X | XXXXX | X | XX |
| @stocksguide_ | X | XXXXX | X | XX |
| @SamFazeli8 | X | XXXXX | X | XX |
| @PersimmonTI | XX | XXXXXX | X | XX |
Sentiment: XX% #
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XX% +7%
1-Year High: XXX% on 2025-05-10
1-Year Low: XX% on 2025-09-14
Most Supportive Themes
- Community Engagement: (45%) Positive sentiment around project updates and community involvement.
- Technological Advancements: (30%) Excitement regarding new features and technological progress.
Most Critical Themes
- Market Volatility: (15%) Concerns about price fluctuations and market uncertainty.
- Competition: (10%) Discussion of competing projects and their potential impact.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXXXX | XX% | XXXXX | XX% | XX | X% |
| Total | XXXXX | XX% | XXXXX | XX% | XX | X% |
Top assets mentioned In the posts about $gmab in the last XX hours
Merus N.V. Common Shares (MRUS) Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) Novo-Nordisk (NVO) AstraZeneca PLC (AZN) AbbVie Inc (ABBV) Eli Lilly and Company (LLY) HCA Healthcare Inc (HCA) Pfizer, Inc. (PFE) Bitcoin Incognito (XBI)
Top topics mentioned In the posts about $gmab in the last XX hours
$gmabco, stocks healthcare, $mrus, stocks, acquisition, $8b, stocks technology, johnson johnson, stocks financial services, $jnj, $nvo, $azn, investment, $abbv, eli lilly, $novcde, $hca, $pfe, denmark, $xbi, $bmrn, $lly, danish krone, $ggndf, breakthrough, $argx, $psnl, stocks banks, targets, combo, stocks communication services, $mrk, $bntx, taiwan semiconductor, $bbio, $pypl, longterm, quarterly earnings, stocks consumer cyclical, stocks bitcoin treasuries, $tdoc, $uhs, $cyh, $novob, $dsv, $elan, investments, stocks industrials, $97share, $googl, $asnd, $sobi, $367b, davis, medtronic, $hrmy, jacob, costa rican colon, coins made in usa, microsoft, $spgi, $danskeco, royalty, ares capital corp, procter gamble, stocks consumer defensive, $209b, $8bn, $55bn, debt, $dwtx, people with, $novo, dough, $36b, $105m, $124m, $meli, salesforce, $dsnky, $43b, $emx, $enlt, all the, $1325sh, approved, $zlab, $pfes, china, make a, stocks utilities, coins defi, coins dao, $dy, $caty, fifth third bancorp, akro akero therapeutics inc, novo, $52b, $54share
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Something tells me $GMAB is about to get eclipsed in folate receptor alpha ADC $LLY $AZN #ESMO25"
X Link @JacobPlieth 2025-10-19T12:42Z 30.9K followers, 3058 engagements
"Fascinating dynamics in ovarian cancer with multiple ADC programs demonstrating a XX% ORR. FRa in the lead ( $GMAB and $LLY in P3s AZ reported today) CDH6 in P2 (Daiichi reporting P2 data later today) and NaPi2b (Tubulis presented strong results today) in P1. All programs are topo1-based so whoever reaches the market first could render most other programs (15 in the clinic) irrelevant assuming efficacy stays similar #ESMO25"
X Link @ohadhammer 2025-10-19T11:28Z 7840 followers, 6482 engagements
"$GMAB Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Updated data from the Phase 1/2 RAINFOL-01 trial showed rinatabart sesutecan (Rina-S) XXX mg/m2 demonstrated 50%confirmed objective response rate (ORR) including two complete responses (CR) regardless of FR expression - A Phase X trial in endometrial cancer is underway U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer"
X Link @MarcJacksonLA 2025-10-18T20:06Z 7582 followers, XXX engagements
"Genmab: Investigational Rinatabart Sesutecan (Rina-S) Achieves Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer $GMAB #Genmab"
X Link @HottestStockNow 2025-10-18T15:40Z 2717 followers, XXX engagements